Login to Your Account

Pharma: clinic roundup

Friday, March 21, 2014
Abbvie Inc., of North Chicago, Ill., said a pivotal phase III trial that will evaluate the use of Humira (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, has been initiated.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription